Identifying microRNAs related to weight loss in pancreatic cancer
Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
This study is trying to find out if certain genetic factors are linked to weight loss in people with pancreatic cancer and to see how this affects different groups of patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Oklahoma Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Trial ID | NCT05275075 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the prevalence of cachexia in patients with resectable pancreatic adenocarcinoma and to identify genetic differences among these patients. It will involve a retrospective examination of 1,395 patients from two cancer centers, combined with a prospective enrollment of 100 volunteers at the University of Oklahoma Stephenson Cancer Center. The study will assess demographic and medical data to explore racial disparities and will analyze tumor samples for microRNA and mRNA expression related to muscle loss. Additionally, optional assessments of hand strength and body composition will be conducted.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with operable pancreatic adenocarcinoma diagnosed within the last year.
Not a fit: Patients with pancreatic adenocarcinoma who are not candidates for surgical resection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of cachexia in pancreatic cancer patients, potentially improving their quality of life.
How similar studies have performed: While there have been studies on cachexia in cancer, this specific approach focusing on microRNAs in pancreatic cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patient, who is ≥ 18 years old at the time of informed consent. 2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma. 3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy. 4. Ability to provide written informed consent and HIPAA authorization. Exclusion Criteria: 1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection. 2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Where this trial is running
Oklahoma City, Oklahoma
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (Recruiting)
Study contacts
- Principal investigator: Ajay Jain, MD — University of Oklahoma Stephenson Cancer Center
- Study coordinator: Lead Nurse
- Email: scc-iit-office@ouhsc.edu
- Phone: 405.271.8777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.